News|Articles|August 15, 2026

DURAVYU Phase 3 DME trials COMO and CAPRI complete enrollment

EyePoint has finished enrolling both pivotal Phase 3 trials evaluating its sustained-release intravitreal insert against aflibercept in diabetic macular edema, setting up a topline readout in late 2027.

EyePoint, Inc. has completed enrollment in COMO (NCT07449936) and CAPRI (NCT07449923), the two global Phase 3 trials of EYP-1901 vorolanib intravitreal insert (DURAVYU) in patients with diabetic macular edema (DME), the company announced July 30, 2026.¹ More than 480 patients were randomized across the 2 studies, with full enrollment reached in roughly 5 months—ahead of the company's projected timeline.¹ Topline 56-week data from both trials are anticipated in the fourth quarter of 2027.¹

Related to this article

October 22nd, 2026

Diabetic macular edema: an inflammatory disease in focus

The epidemiology, inflammatory pathophysiology, diagnosis, and treatment of diabetic macular edema are discussed during Inflammatory Eye Disease Week.

October 20th, 2026

CHMP recommends ranibizumab biosimilar Fovlussea for retinal disease

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

October 20th, 2026

Duravyu misses wet AMD end point again as EyePoint pivots to DME

Second phase 3 trial of Duravyu misses wet AMD noninferiority end point; EyePoint cuts 53% of staff to focus on DME.

October 19th, 2026

Duravyu misses noninferiority end point in phase 3 LUCIA wet AMD trial

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

October 15th, 2026

EC-104 outperforms Ozurdex in phase 2 BETTIS-1 trial for anti-VEGF–resistant DME

Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point and beat the dexamethasone implant on visual and anatomic measures at 24 weeks.